Barclays analyst Matt Miksic raised the firm’s price target on Abbott to $132 from $127 and keeps an Overweight rating on the shares. The analyst increased estimates for 2023 and beyond on the back of the company’s “strong” Q2 results and increased expectations for its underlying businesses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Abbott upgraded, Carvana downgraded: Wall Street’s top analyst calls
- Abbott price target raised to $115 from $110 at Mizuho
- Abbott (NYSE: ABT) Stock Gains on Q2 Beat; Lifts 2023 Revenue Forecast
- Abbott upgraded to Peer Perform from Underperform at Wolfe Research
- Abbott saw ‘very strong growth’ across all four sectors in Q2